<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581020</url>
  </required_header>
  <id_info>
    <org_study_id>P15-349</org_study_id>
    <nct_id>NCT02581020</nct_id>
  </id_info>
  <brief_title>The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects</brief_title>
  <official_title>A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the durability of response and persistence of resistance to
      ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3
      clinical study with these agents for the treatment of chronic hepatitis C.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Hepatitis C virus ribonucleic acid (HCV RNA) levels</measure>
    <time_frame>60 months after completion of the 2D treatment in M12-536 or M13-004 study</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA levels in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis C virus ribonucleic acid (HCV RNA) levels</measure>
    <time_frame>18, 24, 30, 36, 42, 48, 52 months after completion of the 2D treatment in M12-536 or M13-004 study</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA levels in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events (SAEs)</measure>
    <time_frame>Up to 60 month after completion of the 2D treatment in M132-536 or M13-004 study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All serious adverse events will be monitored during the observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with hepatocellular carcinoma</measure>
    <time_frame>Up to 60 month after completion of the 2D treatment in M12-536 or M13-004</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Paritaprevir in Non-structural Viral Protein 3 (NS3)</measure>
    <time_frame>For approximately 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Ombitasvir in Non-structural Viral Protein 5A (NS5A)</measure>
    <time_frame>For approximately 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">436</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who were treated in Study M12-536 or M13-004 with 2D regimen (ombitasvir/
        paritaprevir/ritonavir) and completed 48 weeks of follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants treated in Study M12-536 or M13-004 with the 2D regimen (ombitasvir/
        paritaprevir/ ritonavir) and completed 48 weeks of follow-up, regardless of SVR
        achievement.

        Participants who agree to sign the informed consent.

        Exclusion Criteria:

        Participants treated with a direct-acting antiviral agent (DAA) immediately after Study
        M12-536 or M13-004.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsu Kamitani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie GK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie Japan PMOS Desk</last_name>
    <phone>+81-3-4577-1125</phone>
    <email>AbbVie_JPN_info_clingov@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katsutoshi Hiramatsu</last_name>
    <email>katsutoshi.hiramatsu@abbvie.com</email>
  </overall_contact_backup>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 19, 2015</lastchanged_date>
  <firstreceived_date>October 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese</keyword>
  <keyword>Observation</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
